DDInter894 DDInter178
Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the need for therapeutic monitoring, and serious side effects of secondary cancer and birth defects.
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Hydroxyurea {u} (Compound) resembles {v} (Compound) Acetohydroxamic acid
Hydroxyurea {u} (Compound) treats {v} (Disease) hematologic cancer
Hydroxyurea {u} (Compound) binds {v} (Gene) CYP2D6
Hydroxyurea {u} (Compound) is included by {v} (Pharmacologic Class) Urea
Hydroxyurea {u} (Compound) causes {v} (Side Effect) Infestation NOS
Hydroxyurea {u} may cause a minor interaction that can limit clinical effects when taken with {v} Trovafloxacin
Hydroxyurea {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Hydroxyurea {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pentostatin
Hydroxyurea {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Hydroxyurea {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Hydroxyurea (Compound) resembles Acetohydroxamic acid (Compound)
Hydroxyurea (Compound) treats hematologic cancer (Disease)
Hydroxyurea (Compound) binds CYP2D6 (Gene)
Hydroxyurea (Compound) is included by Urea (Pharmacologic Class)
Hydroxyurea (Compound) causes Infestation NOS (Side Effect)
Hydroxyurea may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin
Hydroxyurea may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Hydroxyurea may lead to a major life threatening interaction when taken with Leflunomide